The Ebola virus is a member of the Filoviridae family (genus Ebolavirus ; order: Mononegavirales ). These viruses are elongated, filamentous structures of variable length.
The virus is thought to be initially acquired from exposure to body fluids or tissue from infected animals such as bats and non-human primates; however, the natural reservoir and mode of transmission to humans has not been confirmed.  Laboratory testing of reservoir competence shows that successful infection is possible in bats and rodents, but not in plants or arthropods.    Animal-to-human transmission may occur during hunting and consumption of the reservoir species or infected non-human primates. The local practice of eating bush meat or food contaminated with bat faeces (3 species of tree-roosting bats have been implicated as a reservoir) is also thought to contribute.
Human-to-human transmission occurs via contact with body fluids from infected patients.  In the early epidemics, the re-use of non-sterile injections was responsible for many healthcare-associated transmissions.  However, while this still remains a risk, most cases result from close physical contact or contact with body fluids (e.g., sweat, blood, faeces, vomit, saliva, genital secretions [including semen], and breast milk) of infected patients.
The level of virus in the blood increases during the course of illness and patients are most infectious in the later stages of the disease (i.e., during diarrhoea, vomiting, and haemorrhage).  Large amounts of virus can be found in the skin and, as sweat may also contain the virus, touching an infected patient may result in transmission.  Super-spreading events in the community are also increasingly recognised as a contributing factor: a funeral of a traditional healer in Sierra Leone in 2015 was linked to 300 cases.  In one study, it was found that super-spreaders were responsible for approximately 61% of infections in the 2014 outbreak. 
In a study to identify the rate of viral shedding in various body fluids, Ebola virus was isolated from saliva, breast milk, stool, tears, and semen up to 40 days after the onset of illness.    The virus can still be detected in semen more than 12 months after recovery from infection, possibly due to testicular tissue being an immunologically-protected site.  This means that sexual transmission may be possible long after the infection has resolved,      and such cases were confirmed during and following the 2014 outbreak.    Ebola virus has also been detected in vaginal fluid.  Viral shedding may continue from urine and sweat. In one recovered patient in Germany, virus was detected in urine 14 days after it was not detected in serum, and in sweat for up to 19 days after it was not detected in serum. 
Infection via the inhalation route has been shown to be possible in non-human primates; however, there is no evidence for airborne transmission in humans.   The possibility of opportunistic airborne transmission of the virus during forceful vomiting (similar to that seen with norovirus infection), and during aerosol-generating procedures associated with critical care interventions, should still be considered.
Outside the endemic areas, Ebola virus infection is rare and is usually an imported infection.  Travellers arriving from affected areas, as well as laboratory scientists and others working with potentially infected materials and animals, are at high risk.
There have been major advances in elucidating the pathogenesis of Ebola virus infection; however, most of the studies have been performed in non-human primate and rodent models.  This is because of the difficulties in conducting human studies in poorly-resourced settings where these infections naturally occur.
The virus genome consists of a single 19 kb strand of negative-sense RNA with 7 viral genes that are transcribed by the viral RNA-dependent RNA polymerase present in the virion. The single strand of RNA is covered by helically-arranged viral nucleoproteins NP and VP30 that are linked by matrix proteins VP24 and VP4 to the lipid bilayer that coats the virion.  There was rapid mutation of the virus in the 2014 outbreak, raising concerns about its ability to evade host immune responses and evolve under pressure of novel therapies.  
The incubation period after infection is 2 to 21 days (typically 3-12 days).  Tissue invasion occurs via infected fluid coming into contact with breaks in the mucosa or skin. This can occur with animal-to-human or human-to-human transmission. Monocytes, macrophages, and dendritic cells are the preferred replication sites for filoviruses on initial infection. Infected cells migrate to the regional lymph nodes, liver, and spleen, thereby disseminating the infection. Ebola virus has a wide cell tropism and is able to infect a variety of different cell types, but extensive viral replication occurs in lymphoid tissue, liver, and the spleen.    It also has the remarkable ability to modulate the expression of genes involved in the host immune response, causing lymphocyte apoptosis and attenuation of the protective effects of interferon.     
The host immune response is crucial and dictates the outcome of infection. Progression to the severe end of the disease spectrum occurs when the virus triggers expression of a host of pro-inflammatory cytokines, including: interferons; interleukins (IL) such as IL-2, IL- 6, IL-8, and IL-10; interferon inducible protein; and tumour necrosis factor (TNF)-alpha.    This, in turn, causes endothelial activation and reduced vascular integrity, release of tissue factor (with associated onset of coagulopathy), and increased nitric oxide levels (with associated hypotension).  Infection leads to lymphocyte depletion through indirect apoptosis (since the virus does not replicate in lymphocytes), and neutrophil suppression via glycoprotein GP.  The most common cause of thrombocytopenia is platelet disappearance from damaged tissue or more generalised virus-induced disseminated intravascular coagulation, where coagulation factors are depleted.  Disseminated intravascular coagulation, along with acute hepatic impairment, predisposes the patient to bleeding complications. Other complications of severe disease include acute kidney injury, hepatitis, and pancreatitis.  Early antibody response, along with reduced lymphocyte depletion, is associated with effective viral clearance and survival.  Flow cytometry, which was used in a treatment centre in Guinea during the 2014 outbreak, demonstrated that T-cell dysregulation (characterised by higher expression of CTLA-4 and PD-1 on CD4 and CD8 cells) was associated with death. This confirms earlier suggestions that an adequate, but controlled, immune response is key to survival. 
The development of shock is still not well understood. Multiple factors may contribute, including: bacterial sepsis, possibly through gut translocation of bacteria; a direct effect of the virus; disseminated intravascular coagulation; or haemorrhage. 
The virus is a member of the Filoviridae family (genus Ebolavirus ). Five distinct species of Ebola virus have been isolated from various epidemics, mainly in African countries, with the exception of the Reston virus that originated in the Philippines.  The latter is remarkable in that it has never caused symptomatic human disease. The other 4 species cause slightly different clinical syndromes of varying severity, and have a reported case fatality rate of 25% to 90% across different outbreaks (the average rate was approximately 50% in most treatment centres in the 2014 outbreak in West Africa).  Zaire ebolavirus and Sudan ebolavirus are especially known for their virulence; the other species are considered to be less virulent. The taxonomy of the virus continues to evolve, with new names emerging for variants of the virus. 
Zaire ebolavirus :
First isolated in 1976 during an outbreak in northern Zaire (now known as the Democratic Republic of the Congo, or DRC).  Seems to be the most virulent of the 5 species and has the highest case fatality rate out of all species.  It is responsible for the outbreak that started in West Africa in 2014. A separate, limited outbreak in the DRC in 2014 was caused by a strain of Zaire ebolavirus distinct from the one that was circulating in West Africa. 
Sudan ebolavirus :
First isolated in 1976 during an outbreak in southern Sudan. Causes an identical syndrome to Zaire ebolavirus ; however, the case fatality rate is less. 
Tai Forest ebolavirus (formerly known as Cote d'Ivoire ebolavirus ):
Only 1 case has been documented in 1994 in a Swiss researcher who performed an autopsy on a dead chimpanzee in Tai National Park in Cote d’Ivoire.  She recovered from the febrile phase of the illness with no haemorrhagic complications.
Bundibugyo ebolavirus :
Discovered in 2007 during a single outbreak in the Bundibugyo district of western Uganda. The isolated virus was identified as a distinct species, distantly related to Tai Forest ebolavirus . 
Reston ebolavirus :
First isolated in Reston, Virginia, US in 1989 where it was found in Cynomolgus monkeys imported from the Philippines. Several workers exposed to infected animals were found to have positive serology, but no clinical symptoms. Since then, the virus has also been isolated from pigs in the Philippines.  
The Filoviridae family of viruses includes: Ebola virus, Marburg virus, and Cuevavirus. Marburg virus is the only other member of this group known to cause human infection. It has been isolated from bats and causes a similar syndrome to Ebola virus infection. Several outbreaks have been reported, often related to animal exposure in mines or caves. 
Use of this content is subject to our disclaimer